Environmental & Social Information • Mar 9, 2017
Environmental & Social Information
Open in ViewerOpens in native device viewer
PRESS RELEASE • PRESS RELEASE • PRESS RELEASE
"Type I Interferon: Friend and Foe Alike"
Paris and Boston, March 9, 2017 – Neovacs (Alternext Paris: ALNEV), a leader in active immunotherapies for the treatment of autoimmune diseases, today announced that Géraldine Grouard-Vogel, PhD., Chief Scientific Officer of Neovacs, will present an update on the Company's IFNα Kinoid program in Lupus, Dermatomyositis and Type 1 Diabetes, at the 2017 Keystone Symposia Conference, taking place March 19 – 23, 2017, in Banff, Alberta, Canada.
Keystone Symposia has a 45-year history of convening open, peer-reviewed conferences that connect the scientific community and accelerate life science discovery. This event, with the theme, "Type I Interferon: Friend and Foe Alike", will bring together key opinion leaders in the field of Type 1 Interferon.
Dr. Grouard-Vogel will give a presentation entitled, "Overexpression of IFNalpha and Derived Diseases: Innovative Approach with a Therapeutic Vaccine IFNalpha Kinoid," during the "Tailoring Type I IFN Interventions to Achieve Cure" session on Thursday, March 23, 2017, from 5:00 – 6:45 PM ET.
Miguel Sieler, Chief Executive Officer of Neovacs, stated, "This presentation confirms a reduction of IFN alpha signature in Lupus patients following IFNα Kinoid administration. Our Phase IIb trial with IFNα Kinoid in Lupus continues to progress, and we are extremely excited about the potential of IFNα Kinoid to become a first-in-class product to treat lupus and other autoimmune diseases, such as dermatomyositis and Type 1 diabetes."
Keystone Symposia will serve as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops held at venues that create an environment conducive to information exchange, generation of new ideas and acceleration of applications that benefit society. http://www.keystonesymposia.org
Neovacs targets pathologies associated with an overproduction of endogenous cytokines. This technology is based on active immunotherapy to generate an immune response through the administration of an immunogenic complex involving the target cytokine to a carrier protein. The intramuscular injection of this Kinoid induces an immune response and stimulates the production of polyclonal antibodies against the target cytokines. It is thus possible to block cytokine overproduction and its pharmacological effects. Several autoimmune and inflammatory diseases (Type 1 diabetes, systemic lupus erythematosus, psoriasis, etc.) are characterized by a disorder of cytokines that are found produced in excess (ex: IFNα). This overproduction will promote inflammation and dysregulation of the immune system
Listed on Alternext Paris since 2010, Neovacs is today a leading biotechnology company focused on an active immunotherapy technology platform (Kinoids) with applications in autoimmune and/or inflammatory diseases. On the basis of the company's proprietary technology for inducing a polyclonal immune response (covered by five patent families that potentially run until 2032) Neovacs is focusing its clinical development efforts on IFNα-Kinoid, an immunotherapy being developed for the indication of lupus, dermatomyositis and also in preclinical trial for Type 1 diabetes. Neovacs is also conducting preclinical development works on other therapeutic vaccines in the fields of auto-immune diseases, oncology and allergies. The goal of the Kinoid approach is to enable patients to have access to safe treatments with efficacy that is sustained in these life-long diseases. www.neovacs.fr
Contacts NEOVACS – Corporate Communication & Investor Relations Charlène Masson +33 1 53 10 93 14 [email protected]
LIFESCI ADVISORS- Investor Relations / Financial Communications Chris Maggos +41 79 367 6254 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.